AlphaVax (Durham, NC) a developer of vaccine products for infectious diseases (influenza & cytomegalovirus lead), biodefense and cancer, has raised approximately $12.65 million in Series E funding. Investors have not been disclosed.
AlphaVax, Inc.: Series E $12.65M
February 20, 2007
Leave a Comment » | 
I - Series E, R - SOUTH EAST, X - Cytomegalovirus, X - Vaccines | 
Permalink
Posted by arubenstein
